BRENTUXIMAB VEDOTIN as Pre-ASCT Induction Therapy in R/R HL Patients Non Responding to IGEV
Status:
Completed
Trial end date:
2017-10-01
Target enrollment:
Participant gender:
Summary
A pilot phase II study with brentuximab vedotin as pre-ASCT induction therapy in
relapsed/refractory Hodgkin's lymphoma patients non-responding to IGEV salvage treatment.